Alzheimer disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• APOE 16
• MAPT 2
• APP 1
• NRF2 0
• NLRP3 0
• TREM2 0
• AKT 0
• BDNF 0
• TDP-43 2
• PI3K 0
• BACE1 0
• GLP-1 1
• MAPK 0
• PPAR 0
• AMPK 0
• mTOR 0
• PSEN1 1
• STING 0
• ERK 0
• NMDA 1
• SNCA 0
• TLR4 0
• JNK 0
• SIRT1 0
• CTNNB1 0
• STAT3 0
• TP53 0
• TNF 0
• HDAC 0
• HIF-1 0
• SGLT2 0
• HMGB1 0
• GPX4 0
• IL-1 0
• PCSK9 0
• COX-2 0
• HSP90 1
• C9orf72 0
• DPP-4 0
• PINK1 0
• IL-17 0
• TFEB 0
• IL-6 0
• PD-L1 0
• VEGF 0
• YAP 0
• AQP4 0
• CD33 0
• IGF1R 0
• MMP-9 0
• CCR5 0
• EGFR 0
• FTO 0
• GBA1 0
• GIP 0
• JAK 0
• KEAP1 0
• PARP 0
• PD-1 0
• ACE2 0

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIMH · F31

  The role of the default mode network in representing and remembering mental states

  Boston College· Chestnut Hill, United States· US$35,733 awarded in fiscal year 2026· until Oct 2028

• U.S. Department of Veterans Affairs · I01

  SleepSMART for Veterans with Insomnia and Mild Cognitive Impairment: A Randomized Clinical Trial

  Va San Diego Healthcare System· San Diego, United States· until Sept 2031

• U.S. Department of Veterans Affairs · IK2

  Cognitive Risk Profiles Among Aging Veterans: Harnessing Big Data for Precision Medicine

  Va San Diego Healthcare System· San Diego, United States· until Sept 2031

• NIH NIA · R03

  Improve and Validate Amyloid Pathology Visualization and Analysis in Intact Brain Samples

  Massachusetts General Hospital· Boston, United States· US$329,220 awarded in fiscal year 2026· until Sept 2028

• NIH NIA · R01

  Enhanced Mapping of Alzheimer's Disease Risk Loci Using Multimodal RNAseq Data

  Emory University· Atlanta, United States· US$653,912 awarded in fiscal year 2026· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Neuroinflammation and Virus Imaging for Smart Therapeutic Approaches (NEUROVISTA)

  Umea Universitet· Umea, Sweden· EU contribution €236,340· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interneuron subtype-specific control of hippocampal memory encoding and retrieval (INSPIRE)

  Universitaetsklinikum Freiburg· Freiburg, Germany· EU contribution €202,125· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Warfare and Agricultural Resilience Nexus in the Ancient Mediterranean (6th. BC - 4th c. AD) (WARNex)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €252,729· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Attentional Control and Mapping in Spatial Navigation: Defining Behavioral Fingerprints for Early Alzheimer’s Risk Detection (SPATIALOS)

  Universitat Jaume I de Castellon· Castellon De La Plana, Spain· EU contribution €209,915· until Apr 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Principles of UFMylation-driven antibacterial defence (UBACT)

  Universite de Geneve· Geneve, Switzerland· EU contribution €1,898,233· until Apr 2032

  The disease is named only in the funder's project summary, not in the title.

10 of 5,135 running projects, newest first. Listed amounts together: US$4.3bn + €321.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 86
• Organoids 36
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 24
• Gene Expression Profiling 176
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 17
• Exome Sequencing 7
• Proteomics 229
• Metabolomics 81
• Mass Spectrometry 62
• Flow Cytometry 16
• Immunohistochemistry 74
• Liquid Biopsy 5
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 676
• Magnetic Resonance Imaging 1001
• Machine Learning 253
• Deep Learning 166
• Cohort Studies 536
• Genome-Wide Association Study 216

• Genetic Determinants of Vascular Dementia: Blood Metabolite Associations and Candidate Therapeutic Target Prioritization.

  Genet Epidemiol, Dec 2026

• Genetic Liability to Opioid Use Disorder and Dementia-Related Biological Pathways: A Mendelian Randomisation Study.

  Int J Geriatr Psychiatry, Nov 2026

• Evaluating the Impacts of Inflammatory Proteins on the Risk of Alzheimer's Disease.

  Mol Neurobiol, Oct 2026

• Genetic evidence supports a cortical neuroprotective role of GLP-1 receptor activation in Alzheimer's disease: A drug-target Mendelian randomization study.

  Alzheimers Dement, Oct 2026

• Associations of Blood Lipid Traits with Cognitive-Related Outcomes and Their Sensitivity to APOE-Region Instrumental Variables: A Mendelian Randomization and Colocalization Study.

  Genes (Basel), Sept 2026

• CRP-albumin-lymphocyte index and multisystem diseases: a phenome-wide Mendelian randomization study.

  Mol Genet Genomics, Sept 2026

• Genetic Prioritization of Plasma Proteins Across Dementia Subtypes: A Proteome-Wide Mendelian Randomization and Bayesian Colocalization Analysis.

  Cell Mol Neurobiol, Sept 2026

• Alzheimer disease and lichen planus: A Mendelian randomization analysis.

  Medicine (Baltimore), Sept 2026

• Multilevel genomic, transcriptomic, and epidemiologic evidence linking diabetic retinopathy to Alzheimer disease.

  J Glob Health, Sept 2026

• Genetic evidence suggests a protective role of immunoglobulin M in Alzheimer's disease.

  Alzheimers Dement, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.